In this interview, News-Medical talks with Andre Alfaro of nanoComposix (now a Fortis Life Sciences company) about the odds presented through lateral flow in the current and future post-COVID period.
Side testing has become much less difficult to describe after COVID, as we can now cite an example that many other people have seen.
A lateral verification is an immediate diagnosis capable of offering quantitative, semi-quantitative or qualitative effects in a matter of minutes. multiple applications.
Everyone is familiar with immediate COVID testing and pregnancy testing, whether they look. The look is selected for those programs because it is economical, accurate, easy to use and ideal when you want a quick reaction without the need for a professional.
COVID has broadened people’s wisdom about the benefits of lateral flow and schooling has been one of the barriers.
People have already been afraid of what they didn’t know. However, with the global adoption of immediate diagnoses, other people need to use those tests to monitor their own health. Am I too stressed?Do I have the flu?How do my organs work?All this can be replicated in a few minutes with a side test.
Thanks to COVID, a new world is being created, and this is a very exciting time.
Our adventure of installing a contract manufacturer for lateral began with nanomaterials. We are a reagent company founded in the early 2000s and started producing nanomaterials primarily for the life sciences sector.
Although nanomaterials programs can range from drug delivery to antimicrobial paint, we found that many other people used traditional nanomaterials of other sizes and surface chemicals to expand diagnostics. So it was a simple decision to expand our features to help consumers expand their products our materials, conjugation and manufacturing wisdom.
nanoComposix (now a Fortis Life Sciences company) is now one of the leading contract organizations and contract brands in the United States. Day after day, we accompany our consumers from initial design to marketing.
No matter where consumers are on the progression spectrum, for example, if it’s about finding markers to treat onchocerciasis in Africa, if they have a concept but don’t know where to start, we can help them. This can mean finding markers, identifying reactive affinities, customizing a testing platform, scaling, managing the supply chain, or manufacturing.
The needs of each verification are different, so instead of a single approach, we build a tailor-made solution for unique problems.
What has replaced the most in the last two years is education. People now know what flow looks like because COVID has forced other people to broaden that understanding. People know how to take a sample, combine it with a buffer, add this solution to a strip, and interpret a result. Not long ago, this would have been unrealistic, as indicated by the number of over-the-counter LFA controls on the market. The complexity gap between a pregnancy check and a COVID check is significant, and we have closed that hole totally by the pandemic.
Knowing that we have billions of case studies of other people, as well as immediate over-the-counter lateral flow tests, corporations are not investing in new cutting-edge tactics to put those tests in the hands of the everyday user for preventive medicine, fitness control. , follow-up and more.
We call this individualized physical attention. People are now more comfortable with a fitness tracking platform that they can use at home to schedule a doctor’s appointment.
People saw a doctor and took a blood pattern to check for cholesterol or other things. I think it would be very favorable to be able to do it at home, at a fraction of the charge for the health care formula and the individual.
First, the challenge of presenting the chemistry and biology that occur on tape. The aspect is a dynamic platform where we want everything to happen temporarily in a very small space. Most central labs use giant analyzers that can perform several steps to make the check faster or more sensitive. You don’t have that luxury in aspectArray
The next challenge is to expand a tradition platform that meets all product requirements. This can involve a lot of tradition. For example, do we want a traditional cassette?Do we want specialized readers? All those things have the profile of the target product, which presents many difficulties.
The main hurdle small businesses face is that they have to expand a platform from scratch, while giant corporations put new tests on an existing platform. Typically, giant corporations already have a pre-existing platform for integrating a new test. This makes the adventure easier and easier, as there are fewer questions to answer.
For giant companies, design constraints can be both smart and bad, because if we use an existing platform and don’t have the ability to rotate all the knobs, it limits functions around imaginable solutions.
While small businesses have the added burden of creating a new platform, they also have the ability to customize every aspect of the platform to meet the requirements of the test they are developing. This means many imaginable answers to potential problems during development. .
There are bad scenarios for small and giant companies, and I would say they are on an equal footing when it comes to marketing the product, as long as they have the budget to carry it out.
Developing an advertising product is expensive, especially if you have to go through clinical trials, so it’s important for any company to make sure they’ve allocated budgets beforehand.
We can leverage our expertise in creating standalone sidestream platforms to drive progression and shorten time to market. Along with our deep wisdom on product progression, we have also vertically incorporated the critical parts of product progression under one roof. for a seamless transition from progression to commercialization.
We will be offering a combination of antibodies, nanomaterials, production functions and progression expertise. That’s what we bring to the table when consumers talk to us, and we can answer more questions from those studies faster because we have integration across all grades in terms of what’s required for product progression.
It’s about taking and empowering other people to control their own well-being. This means decentralizing physical care, so that it’s no longer just in a doctor’s workplace. COVID moves the narrative of transforming your doctor’s hospital or workplace if you’re sick, so you can diagnose yourself from the comfort of your home.
This provides many benefits, as it reduces the spread of infectious diseases and reduces the burden on fitness systems.
In addition to the detection of infectious diseases, we can also use lateral as a component of well-being or what we call “surveillance”. Monitoring involves tracking rapid biomarkers related to overall well-being, for example, PCR or troponin, markers that are regularly tracked every time you go to the doctor in case something is going wrong.
Decentralizing fitness care, empowering Americans to monitor their fitness, and independently tracking their fitness are important steps, and COVID was the triggering event that sparked much of that.
Lateral flow tests can be used for everything from infectious diseases to agriculture, and everything in between.
Veterinary care is a good example. Lateral is a wonderful way to monitor the physical condition of our pets. Whether it serves the kidneys or cats, to see if the tick that bit your dog tested positive for Lyme disease, lateral can help.
We can use side tests to track any chemicals or proteins related to neurological health. Side tests don’t replace an MRI, but before you jump to those much-loved tests, we can help you track and monitor the quick markers to see if there’s possibly a challenge or not.
Head trauma is a perfect example. It’s high-risk but difficult to diagnose without a CT scan, and a large number of other people who go to the emergency room saying they have a concussion don’t, but they get tested.
It would make all the difference if we could do those tests at home.
Absolutely, with the proviso that the road to commercialization is long. This is due to the dangers related to the effects and as such, the FDA is closely monitoring this.
Since the consequences of a false-negative cancer diagnosis are so severe, the validation procedure is lengthy. That is why lateral is not yet widely used in this space. But we can do a lot of monitoring and control because the library of biomarkers related to express cancer is relatively giant and well characterized.
For example, postoperative follow-up of recurrences is a use of lateral flow. Diagnostics are also a very clever use of lateral flow. Once the clinical studies are completed, this would be the next step, as we want longitudinal studies that show that the tests are accurate enough not to pose a threat to people.
There are many lateral programs in the agricultural space, ranging from evaluating livestock to make sure they are healthy and not spreading disease to checking GMO content to meet food standards.
There are already a multitude of tactics for the food industry; cattle and GMO content are just the tip of the iceberg.
I do this basically because they are reasonable and easy to use. If you can create something affordable and easy to use, there will be a utility.
The big question is whether the side checks are delicate or accurate enough, and that depends on the check itself. Some checks have been shown to be more accurate than PCR, for example, but each check is different.
This superior functionality is due to inventions in this field, such as nanoComposix gold nanoshells (now a Fortis Life Sciences company) that offer superior sensitivity. If it meets the sensitivity required to test an undeniable-looking flow, there’s rarely much festival in terms of load and ease of implementation.
As one of the largest control progression houses and high-performance brands in the country, nanoComposix will be at the forefront of the lateral flow revolution. We continue to innovate and expand new nanomaterials and proteins to make higher doses in the future, and we are fully incorporated to temporarily incorporate those new products into any side-flow product.
Andre Alfaro earned his B. S. in Human Biology and Bachelor’s Degree in Clinical Psychology at the University of California, San Diego, where he spent several years characterizing surface markers in cancer stem cells for prospective use as targets for nanoparticle delivery systems of cancer vaccines. He then joined Astute Medical in 2008 where he began a career emerging and commercializing dozens of in vitro diagnostic tests on side platforms and ELISAs for multiple disease indications. In 2018, he joined the nanoComposix team (now a Fortis Life Sciences company) to bring his 10 years of development, quality and regulatory education to the side group.
Fortis Life Sciences is a strategic platform that provides capital, expertise and operational resources to enable the expansion and goodwill of founder-led life sciences tool companies. Fortis Life Sciences was founded in 2020, with the vision of creating a life sciences company world-class products combined with the best visitor experience.
Fortis Life Sciences
Use one of the following to cite this article in your essay, article, or report:
AAP
Fortis Life Sciences. (2022, March 16). Side tests: the odds beyond COVID-19. Actualités-Médicale. Retrieved April 1, 2022, https://www. news-medical. net/news/20220317/Lateral–assays-The-probabilities-beyond-COVID-19. aspx.
deputy
Fortis Life Sciences”. Side Testing: The Odds Beyond COVID-19. “News-Medical. 01 April 2022. .
Chicago
Fortis Life Sciences”. Side Testing: The Odds Beyond COVID-19. “News-Medical. . aspx. (accessed April 1, 2022).
Harvard
Fortis Life Sciences. 2022. Lateral Flow Testing: The Possibilities Beyond COVID-19. News-Medical, accessed April 1, 2022, https://www. news-medical. net/news/20220317/Lateral-flow-assays-The-possibilities-beyond-COVID-19. aspx.
News-Medical. net – An AZoNetwork website
Ownership and operation through AZoNetwork, © 2000-2022